Hikma Pharmaceuticals (LSE:HIK) FCF Margin % : 28.87% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Hikma Pharmaceuticals's Free Cash Flow for the six months ended in Dec. 2023 was £330 Mil. Hikma Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was £1,144 Mil. Therefore, Hikma Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 28.87%.

As of today, Hikma Pharmaceuticals's current FCF Yield % is 9.87%.

The historical rank and industry rank for Hikma Pharmaceuticals's FCF Margin % or its related term are showing as below:

LSE:HIK' s FCF Margin % Range Over the Past 10 Years
Min: 5.28 Med: 14.69 Max: 20.62
Current: 18.53

During the past 13 years, the highest FCF Margin % of Hikma Pharmaceuticals was 20.62%. The lowest was 5.28%. And the median was 14.69%.

LSE:HIK's FCF Margin % is ranked better than
89.46% of 1025 companies
in the Drug Manufacturers industry
Industry Median: -0.67 vs LSE:HIK: 18.53

Hikma Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Hikma Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals FCF Margin % Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

12.96

10.25

16.02

14.30

18.54

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															20.87	4.12	23.77	8.06	28.87

Competitive Comparison of Hikma Pharmaceuticals's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikma Pharmaceuticals's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's FCF Margin % falls into.

Hikma Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Hikma Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	421.07	/	2271.25
	=	18.54 %

Hikma Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	330.22	/	1143.92
	=	28.87 %

Hikma Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals (LSE:HIK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIKl:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (LSE:HIK) Headlines

No Headlines